Alkermes Reports Prelim. Results From Phase 3 Antipsychotic Efficacy Study Of ALKS 3831 For Treatment Of Schizophrenia: Showed Efficacy Statistically Superior To Placebo, Similar To Olanzapine In ENLIGHTEN-1 Study